Skip to content

Study · Non-randomized trial · 2011

2 results

[Noopept in the treatment of mild cognitive impairment in patients with stroke].

Amelin AV, Iliukhina AIu, Shmonin AA

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova1 Jan 2011

PMID22500312 (opens in a new tab)PepBankPUB-22500312
Publisher pageAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with stroke, noopept improved cognitive functions after 2 months in the main group compared with controls, as shown by MMSE scores and lateral and categorical associations.

    In plain wordsIn patients with stroke, noopept improved cognitive test results after 2 months compared with controls.

    Peptide
    Noopept (omberacetam)
    Outcome
    IncreaseCognitive functions (MMSE scores, lateral and categorical associations)
    Study

    n: not reported in source

    Comparator
    Controls
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    20 mg daily · 2 monthsAs given in this study (human).

    Source sentences

    Summary
    An analysis of MMSE scores and lateral and categorical associations revealed the significant improvement of cognitive functions after 2 months in patients of the main group compared to the controls.
    2 context sentences
    Summary · context
    The present open prospective study included 60 patients with stroke treated with noopept during 12 months.
    Summary · context
    Cognitive functions were assessed before and after treatment using neuropsychological tests.
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with stroke, global assessment showed mild improvement with Noopept, while controls showed no change.

    In plain wordsIn patients with stroke, the global assessment showed mild improvement with Noopept and no change in controls.

    Peptide
    Noopept (omberacetam)
    Outcome
    IncreaseGlobal assessment of efficacy
    Study

    n: not reported in source

    Comparator
    Controls
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    20 mg daily · 2 monthsAs given in this study (human).

    Source sentences

    Summary
    The global assessment of efficacy revealed the mild improvement in the main group while no changes were found in the control group.
    2 context sentences
    Summary · context
    The present open prospective study included 60 patients with stroke treated with noopept during 12 months.
    Summary · context
    Cognitive functions were assessed before and after treatment using neuropsychological tests.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.